Designed specifically for the tumor subspecialty, hear the latest research with key takeaways that help practices update and improve approaches to patient care. The session provides 3.25 CME.

Pricing

Faculty

Learning Objectives

After completing this educational activity, participants should be able to:

• Discuss research updates in tumor neurosurgery
• Apply updates in tumor neurosurgery to practice

CME Accreditation

The AANS designates this internet enduring material activity for a maximum of 3.25 AMA PRA Category 1 Credits™.

Disclosure Information

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), the AANS must ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational activities. In accordance with the ACCME’s Standards for Commercial Support, the AANS is required to disclose to the activity audience the relevant financial relationships of the planners, faculty and any other individual in a position to control content of this activity.

Please find the relevant financial relationships disclosed below for all individuals in control of content. All conflicts of interest have been resolved in accordance with ACCME Standards for Commercial Support.

Planners, faculty and any other individuals in control of content not listed have indicated that they have no relevant financial relationships to disclose for this activity.

Disclaimer

The opinions expressed in this educational activity are those of the author and do not necessarily represent the views of the grant provider or the AANS. This educational activity does not endorse one particular type of instrumentation, nor is it intended to dictate an exclusive course of management. It presents one of numerous recognized methods of clinical practice for consideration by physicians for incorporation into their practices. Variations of practice taking into account the needs of the individual patient, resources and limitations unique to the institution or type of practice may be appropriate. Disclosure about patient confidentiality, standards of care or course of management does not imply endorsement or disapproval of products.

Please Note: It is recognized that the use of non-FDA approved devices is described in some of the published material, but these techniques are often the standard of care and may be of value to the patients served.

Accreditation Designation

The AANS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The AANS designates this internet enduring material activity for a maximum of 3.25 AMA PRA Category 1 Credits.™

Physicians should claim only credit commensurate with the extent of their participation in the activity.

Term of approval is for three years, beginning from 05/27/2020 until 05/27/2023.

© 2020 American Association of Neurological Surgeons

Brain metastases are commonly treated as a part of a general neurosurgical practice. Major changes in the management of brain metastases have occurred in the past decade. This webinar covers the management of brain metastases, including:

• Stereotactic Radiosurgery (SR);
• Post-SR Metastases;
• Surgical Resection of BM from Eloquent Cortex;
• Targeted Therapy; and
• Case Presentations Discussing Different Management Strategies.

Pricing

Faculty

Learning Objectives

Upon completion of this activity, participants should be able to:

• Describe advanced management strategies for brain metastases, including resection, stereotactic radiosurgery and immune therapy.
• Describe complex stereotactic radiosurgical planning for large metastases, brainstem metastases and cavities before and after resection.
• Diagnose and manage post-stereotactic radiosurgery (post-SR) brain metastases. 
• Describe the advantages and shortcomings of neuroimaging techniques in evaluating post-SR brain metastases.
• Develop an understanding of the role of corticosteroids, bevacizumab and craniotomy in the treatment of post-SR adverse radiation effect/radiation necrosis.
• Describe the current literature on the role of immune therapy as a primary treatment for brain metastases. 

CME Accreditation

The AANS designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. 

Disclaimer

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the AANS. This educational activity does not endorse one particular type of instrumentation, nor is it intended to dictate an exclusive course of management. It presents one of numerous recognized methods of clinical practice for consideration by physicians for incorporation into their practices. Variations of practice taking into account the needs of the individual patient, resources, and limitations unique to the institution or type of practice may be appropriate. Disclosure about patient confidentiality, standards of care, or course of management does not imply endorsement or disapproval of products.

Please note: It is recognized that the use of non-FDA approved devices is described in some of the published material, but these techniques are often the standard of care and may be of value to the patients we serve.

Disclosure Information

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), the AANS must ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational activities. In accordance with the ACCME’s Standards for Commercial Support, the AANS is required to disclose to the activity audience the relevant financial relationships of the planners, faculty and any other individual in a position to control content of this activity.

Please find the relevant financial relationships disclosed below for all individuals in control of content. All conflicts of interest have been resolved in accordance with ACCME Standards for Commercial Support.

Planners, faculty and any other individuals in control of content not listed have indicated that they have no relevant financial relationships to disclose for this activity.

None

Accreditation

The AANS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The AANS designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity was published in 5/19/2020. Credit may be obtained until 5/19/2023.

Faculty speak to malignant brain tumor surgery and its technical adjuncts for neurosurgeons in the operating room. Earn 3.0 CME and learn about the strategies for intraoperative diagnosis and imaging, tumor resection, noninvasive catheter-based treatments as well as how to recognize the validity of emerging techniques in intraoperative brain tumor visualization.

Pricing

Faculty

Learning Objectives

Upon completion of this activity, participants should be able to:

• Apply technological adjuncts that aid in the intraoperative diagnosis and imaging of malignant brain tumors in the operating room during surgery.
• Distinguish technological adjuncts that aid in the resection of malignant brain tumors.
• Demonstrate technological adjuncts that enable noninvasive catheter-based treatments of malignant brain tumors.
• Appraise technological adjuncts that enable minimally invasive, but complete resection, of malignant brain tumors in the operating room.
• Recognize the scientific basis and proposed clinical applications of emerging techniques in intraoperative brain tumor visualization. 

CME Accreditation

The AANS designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits™. 

Disclaimer

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the AANS. This educational activity does not endorse one particular type of instrumentation, nor is it intended to dictate an exclusive course of management. It presents one of numerous recognized methods of clinical practice for consideration by physicians for incorporation into their practices. Variations of practice taking into account the needs of the individual patient, resources, and limitations unique to the institution or type of practice may be appropriate. Disclosure about patient confidentiality, standards of care, or course of management does not imply endorsement or disapproval of products.

Please note: It is recognized that the use of non-FDA approved devices is described in some of the published material, but these techniques are often the standard of care and may be of value to the patients we serve.

Disclosure Information

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), the AANS must ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational activities. In accordance with the ACCME’s Standards for Commercial Support, the AANS is required to disclose to the activity audience the relevant financial relationships of the planners, faculty and any other individual in a position to control content of this activity.

Please find the relevant financial relationships disclosed below for all individuals in control of content. All conflicts of interest have been resolved in accordance with ACCME Standards for Commercial Support.

Planners, faculty and any other individuals in control of content not listed have indicated that they have no relevant financial relationships to disclose for this activity.

Manish K. Aghi, MD, PhD, FAANS

Kaisorn Lee Chaichana, MD, FAANS

Alexandra J. Golby, MD, FAANS

Accreditation

The AANS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The AANS designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity was published in 5/19/2020. Credit may be obtained until 5/19/2023.